PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
London (PRWEB) October 29, 2013 -- PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
The Indian pharmaceutical market consists primarily of domestically manufactured generics and is therefore not affected by erosion of the sales of patented drugs when these products enter the market. By integrating only generics into the market, medicines can be easily distributed to the large population being served without restricting access by requiring a co-payment from private insurance companies. This model of healthcare does not attract newly-developed agents, but rather those that are cost-effective. Given such limitations for actively-patented branded medications, the Indian pharmaceutical market is not likely to see the introduction of any new AD drugs during the forecast period.
Scope
-Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in India from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting India Alzheimer’s Disease market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in India
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer’s Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
4.3 India 40
4.3.1 Diagnosis 40
4.3.2 Clinical Practice 40
5 Competitive Assessment 43
5.1 Overview 43
5.2 Strategic Competitor Assessment 43
5.3 Product Profiles - Major Brands 46
5.3.1 Aricept (donepezil hydrochloride) 46
5.3.2 Exelon (rivastigmine, rivastigmine tartrate) 50
5.3.3 Razadyne (galantamine hydrobromide) 55
5.3.4 Namenda (memantine hydrochloride) 59
6 Opportunity and Unmet Need 63
6.1 Unmet Needs Overview 63
6.1.1 Public Awareness 65
6.1.2 Specialized Institutions at Local Levels 66
6.1.3 Screening and Diagnosis 66
6.1.4 Early Intervention 67
6.1.5 Improved Clinical Trial Design 68
6.1.6 Effective Therapy 69
6.1.7 Behavioral Treatments 70
6.2 Gap Analysis 70
6.2.1 Disease Prevention 71
6.2.2 Diagnosis from Biomarkers 72
6.2.3 Behavioral Therapies 73
7 Pipeline Assessment 74
7.1 Overview 74
7.2 Early-Stage Pipeline Assessment 74
7.3 AD Pipeline by Mechanism of Action 76
7.4 Enzymatic Processing 77
7.5 Immunization 78
7.6 Anti-Aggregation 78
7.7 “Me-Too” 79
7.8 Novel Therapeutic Approaches 80
7.9 Technology Trends Analytic Framework 80
7.10 Promising Drugs in Clinical Development 81
8 Market Outlook 83
8.1 India 83
8.1.1 Forecast 83
8.1.2 Key Events 85
8.1.3 Drivers and Barriers 85
9 Appendix 88
9.1 Bibliography 88
9.2 Abbreviations 98
9.3 Methodology 104
9.4 Forecasting Methodology 104
9.4.1 Diagnosed AD patients 104
9.4.2 Percent Drug-treated Patients 105
9.4.3 Drugs Included in Each Therapeutic Class 105
9.4.4 General Pricing Assumptions 106
9.4.5 Generic Erosion 108
9.5 Physicians and Specialists Included in this Study 108
9.6 About the Authors 109
9.6.1 Author 109
9.6.2 Global Head of Healthcare 110
9.7 About GlobalData 111
9.8 Disclaimer 111
List of Tables
Table 1:Symptoms of AD 30
Table 2:Guidelines for the Treatment of AD 37
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 38
Table 4:Leading Branded Treatments for AD, 2013 44
Table 5:Product Profile - Aricept 47
Table 6:Aricept SWOT Analysis, 2013 50
Table 7:Product Profile- Exelon 51
Table 8:Exelon SWOT Analysis, 2012 54
Table 9:Product Profile - Razadyne 56
Table 10:Razadyne SWOT Analysis, 2013 58
Table 11:Product Profile- Namenda 60
Table 12:Namenda SWOT Analysis, 2013 62
Table 13:Overall Unmet Needs - Current Level of Attainment 64
Table 14:Clinical Unmet Needs - Gap Analysis, 2013 71
Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 81
Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 81
Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 82
Table 18:Sales Forecasts ($m) for AD in India, 2012-2022 83
Table 19:Key Events Impacting Sales for AD in India, 2012-2022 85
Table 20:AD Market in India - Drivers and Barriers, 2012-2022 85
List of Figures
Figure 1:Atrophy of the Brain in AD 19
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 21
Figure 3:Non-Amyloidogenic Metabolism of APP 23
Figure 4:Amyloidogenic Metabolism of APP 24
Figure 5:Neurofibrillary Tangles 26
Figure 6:Oxidative Damage Due to Free Radicals 28
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 45
Figure 8:AD - Pipeline Drugs by Target, 2012 75
Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 82
Figure 10:Sales for AD in India by Drug Class, 2012-2022 84
Read the full report:
PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article